Versant Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Versant Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	–	–	1654
2019 Q3	$0	Hold	1	–	–	﹤0.01%	1658
2019 Q2	$0	Sell	1 -5	-83%	-$6.14K	﹤0.01%	1793
2019 Q1	$9K	Sell	6 -5	-45%	-$9.01K	﹤0.01%	955
2018 Q4	$19K	Buy	11 +1	+10%	+$2.18K	0.01%	567
2018 Q3	$24K	Sell	10 -1	-9%	-$3.1K	0.01%	556
2018 Q2	$37K	Hold	11	–	–	0.02%	393
2018 Q1	$32K	Hold	11	–	–	0.01%	440
2017 Q4	$28K	Sell	11 -3	-21%	-$8.53K	0.01%	514
2017 Q3	$39K	Buy	14 +4	+40%	+$10.5K	0.02%	342
2017 Q2	$24K	Buy	10 +4	+67%	+$7.92K	0.01%	523
2017 Q1	$15K	Buy	+6	New	+$17.3K	0.01%	701
2016 Q4	–	Hold	0	–	-$1K	–	1576
2016 Q3	–	Hold	0	–	–	–	1333
2016 Q2	–	Sell	-1	Closed	-$3.25K	–	1302
2016 Q1	$3K	Sell	1 -1	-50%	-$4.15K	﹤0.01%	1087
2015 Q4	$7K	Buy	+2	New	+$8.74K	﹤0.01%	866

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Versant Capital Management's ACOR Position: Q4 2019 in Review

Versant Capital Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 1 share.

Versant Capital Management first reported a position in ACOR in Q4 2015 and held it in 13 quarters. The position peaked at $39K in Q3 2017. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

Versant Capital Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
Versant Capital Management sold 1 Acorda Therapeutics share in Q4 2019.
Versant Capital Management first reported a position in Acorda Therapeutics in Q4 2015 and held it in 13 quarters.
Versant Capital Management's Acorda Therapeutics position peaked at $39K in Q3 2017.
121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Versant Capital Management's 13F filing for Q4 2019, filed 28 Jan 2020.